Cephalon exercises option for Lupuzor licence
This article was originally published in Scrip
Executive Summary
Cephalon will pay ImmuPharma $30 million for exercising its option to license the worldwide rights to Lupuzor (IPP-201101), ImmuPharma's investigational drug for systemic lupus erythematosus.